Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 62.

Brown, Jennifer R, Hamadani, Mehdi, Hayslip, John, Janssens, Ann, Wagner-Johnston, Nina, Ottmann, Oliver, Arnason, Jon, Tilly, Hervé, Millenson, Michael, Offner, Fritz, Gabrail, Nashat Y, Ganguly, Siddhartha, Ailawadh, Sikander, Kasar, Siddha, Kater, Arnon P, Doorduijn, Jeanette K, Gao, Lei, Lager, Joanne J, Wu, Bin, Egile, Coumaran and Kersten, Marie José 2018. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology 5 (4) , e170-e180. 10.1016/S2352-3026(18)30030-9
Item availability restricted.
file

Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver and Sewell, Andrew 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3) , pp. 311-322. 10.1182/blood-2017-05-787598
file

Pfeifer, Heike, Raum, Katharina, Markovic, Sandra, Nowak, Verena, Fey, Stephanie, Obländer, Julia, Pressler, Jovita, Böhm, Verena, Brüggemann, Monika, Wunderle, Lydia, Hüttmann, Andreas, Wäsch, Ralph, Beck, Joachim, Stelljes, Matthias, Viardot, Andreas, Lang, Fabian, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Serve, Hubert, Weiss, Christel, Goekbuget, Nicola, Ottmann, Oliver G. and Nowak, Daniel 2018. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood 131 , pp. 1464-1475. 10.1182/blood-2017-07-796862
Item availability restricted.
file

Schlenk, Richard, Krauter, Jürgen, Raffoux, Emmanuel, Kreuzer, Karl-Anton, Schaich, Markus, Noens, Lucien, Pabst, Thomas, Vusirikala, Madhuri, Bouscary, Didier, Spencer, Andrew, Candoni, Anna, Sierra Gil, Jorge, Berkowitz, Noah, Weber, Hans-Jochen and Ottmann, Oliver 2018. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials. Haematologica 103 , e25-e28. 10.3324/haematol.2017.172411
file

Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M and Ottmann, Oliver 2017. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts. Leukemia 31 (12) , pp. 2799-2806. 10.1038/leu.2017.159
file

Ottmann, Oliver 2017. Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. American Journal of Case Reports 18 , pp. 1099-1109. 10.12659/AJCR.904956
file

Nagel, Inga, Bartels, Marius, Duell, Johannes, Oberg, Hans-Heinrich, Ussat, Sandra, Bruckmueller, Henrike, Ottmann, Oliver, Pfeifer, Heike, Trautmann, Heiko, Gökbuget, Nicola, Caliebe, Almuth, Kabelitz, Dieter, Kneba, Michael, Horst, Heinz-August, Hoelzer, Dieter, Topp, Max S., Cascorbi, Ingolf, Siebert, Reiner and Brüggemann, Monika 2017. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130 (18) , pp. 2027-2031. 10.1182/blood-2017-05-782888
file

Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H and Ottmann, Oliver 2017. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia 31 (11) , pp. 2523-2525. 10.1038/leu.2017.242
file

Hantschel, Oliver and Ottmann, Oliver G. 2017. Allosterische Kinaseinhibitoren. Der Onkologe 23 (8) , pp. 626-631. 10.1007/s00761-017-0244-4
file

Both, Anna, Krauter, Jürgen, Damm, Frederik, Thol, Felicitas, Göhring, Gudrun, Heuser, Michael, Ottmann, Oliver, Lübbert, Michael, Wattad, Mohammed, Kanz, Lothar, Schlimok, Günter, Raghavachar, Aruna, Fiedler, Walter, Kirchner, Hartmut, Brugger, Wolfram, Schlegelberger, Brigitte, Heil, Gerhard, Ganser, Arnold and Wagner, Katharina 2017. The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology 96 (6) , pp. 895-904. 10.1007/s00277-017-2967-0

Martinelli, Giovanni, Boissel, Nicolas, Chevallier, Patrice, Ottmann, Oliver, Gökbuget, Nicola, Topp, Max S., Fielding, Adele K., Rambaldi, Alessandro, Ritchie, Ellen K., Papayannidis, Cristina, Sterling, Lulu Ren, Benjamin, Jonathan and Stein, Anthony 2017. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. Journal of Clinical Oncology 35 (16) , pp. 1795-1802. 10.1200/JCO.2016.69.3531
file

Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A., Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver, Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S. and Bargou, Ralf 2017. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica 102 (4) , e132-e135. 10.3324/haematol.2016.153957
file

Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, Oliver and Rieger, M A 2017. Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Leukemia 31 (3) , pp. 731-734. 10.1038/leu.2016.315
file

Oelsner, Sarah, Friede, Miriam E., Zhang, Congcong, Wagner, Juliane, Badura, Susanne, Bader, Peter, Ullrich, Evelyn, Ottmann, Oliver, Klingemann, Hans, Tonn, Torsten and Wels, Winfried S. 2017. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy 19 (2) , pp. 235-249. 10.1016/j.jcyt.2016.10.009
file

Oelsner, Sarah, Wagner, Juliane, Friede, Miriam E., Pfirrmann, Verena, Genssler, Sabrina, Rettinger, Eva, Buchholz, Christian J., Pfeifer, Heike, Schubert, Ralf, Ottmann, Oliver, Ullrich, Evelyn, Bader, Peter and Wels, Winfried S. 2016. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. International Journal of Cancer 139 (8) , pp. 1799-1809. 10.1002/ijc.30217

Giebel, Sebastian, Czyz, Anna, Ottmann, Oliver, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Cornelissen, Jan J., Esteve, Jordi, Gorin, Norbert-Claude, Savani, Bipin, Schmid, Christoph, Mohty, Mohamad and Nagler, Arnon 2016. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Cancer 122 (19) , pp. 2941-2951. 10.1002/cncr.30130
file

Wojcik, Bartosch, Lang, Fabian, Oellerich, Thomas, Falkenburg, J. H., Brueggemann, Monika, Schroeder, Timm, Serve, Hubert, Ottmann, Oliver and Rieger, Michael 2016. Plastic surface marker expression in adult acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Experimental Hematology 44 (9) , S108-S108. 10.1016/j.exphem.2016.06.240

Rousselot, Philippe, Coude, Marie Magdelaine, Gokbuget, Nicola, Passerini, Carlo Gambacorti, Hayette, Sandrine, Cayuela, Jean-Michel, Huguet, Francoise, Leguay, Thibaut, Chevallier, Patrice, Salanoubat, Celia, Bonmati, Caroline, Alexis, Magda, Hunault, Mathilde, Glaisner, Sylvie, Agape, Philippe, Berthou, Christian, Jourdan, Eric, Fernandes, Jose, Sutton, Laurent, Banos, Anne, Reman, Oumedaly, Lioure, Bruno, Thomas, Xavier, Ifrah, Norbert, Lafage-Pochitaloff, Marina, Bornand, Anne, Morisset, Laure, Robin, Valerie, Pfeifer, Heike, Delannoy, Andre, Ribera, Josep, Bassan, Renato, Delord, Marc, Hoelzer, Dieter, Dombret, Herve and Ottmann, Oliver 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128 (6) , pp. 774-782. 10.1182/blood-2016-02-700153
file

Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, Oliver, Ruf, P., Lindhofer, H. and Al-Batran, S.-E. 2016. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16 (1) , p. 420. 10.1186/s12885-016-2449-0
file

Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver and Tonn, Torsten 2016. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. Journal of Cellular and Molecular Medicine 20 (7) , pp. 1287-1294. 10.1111/jcmm.12810

Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Oliver, Ruthardt, Martin and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46.

Vetter, Tina, Borowski, Andreas, Wohlmann, Andreas, Ranjan, Nilabh, Kuepper, Michael, Badura, Susanne, Ottmann, Oliver and Friedrich, Karlheinz 2016. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients. Leukemia Research 40 , pp. 38-43. 10.1016/j.leukres.2015.10.003

Bug, Gesine, Burchert, Andreas, Wagner, Eva-Maria, Kroeger, Nicolaus, Jedlickova, Zuzana, Gueller, Saskia, Metzelder, Stephan, Wolf, Andrea, Bader, Peter, Huenecke, Sabine, Serve, Hubert and Ottmann, Oliver 2015. Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial. Blood 126 (23) , 4344.

Ottmann, Oliver, Alimena, Giuliana, DeAngelo, Daniel J., Goh, Yeow-Tee, Heinrich, Michael C., Hochhaus, Andreas, Hughes, Timothy P., Mahon, Francois-Xavier, Mauro, Michael J., Minami, Hironobu, Nguyen, Marie Huong, Rea, Delphine, Steegmann, Juan Luis, Chatterjee, Arkendu, Iyer, Varsha, Martinez, Noelia, Vanasse, Gary J. and Dong-Wook, Kim 2015. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single - agent activity in a Phase I study of patients with CML with failure of prior TKI therapy. Blood 126 (23) , 138.

Leibundgut, Elisabeth Oppliger, Haubitz, Monika, Burington, Bart, Ottmann, Oliver, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Roeth, Alexander, Snyder, David S. and Baerlocher, Gabriela M. 2015. Dynamics of mutations in patients with ET treated with Imetelstat. Blood 126 (23) , 57.

Giagounidis, Aristoteles, Platzbecker, Uwe, Germing, Ulrich, Goetze, Katharina, Kiewe, Philipp, Mayer, Karin Tina, Ottmann, Oliver, Radsak, Markus, Wolff, Thomas, Haase, Detlef, Hankin, Monty, Wilson, Dawn, Zhang, Xiaosha, Laadem, Adberrahmane, Sherman, Matthew L. and Attie, Kenneth M. 2015. Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood 126 (23) , 92.

Platzbecker, Uwe, Germing, Ulrich, Giagounidis, Aristoteles, Goetze, Katharina, Kiewe, Philipp, Mayer, Karin Tina, Ottmann, Oliver, Radsak, Markus, Wolff, Thomas, Haase, Detlef, Hankin, Monty, Wilson, Dawn, Zhang, Xiaosha, Laadem, Abderrahmane, Sherman, Matthew L. and Attie, Kenneth M. 2015. Biomarkers of ineffective erythropoiesis predict response to Luspatercept in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): final results from the phase 2 PACE-MDS study. Blood 126 (23) , 2862.

Martinelli, Giovanni, Dombret, Herve, Chevallier, Patrice, Ottmann, Oliver, Goekbuget, Nicola, Topp, Max S., Fielding, Adele K., Sterling, Lulu Ren, Benjamin, Jonathan and Stein, Anthony Selwyn 2015. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) following treatment with blinatumomab: results from a Phase 2 single-arm, multicenter study (ALCANTARA). Blood 126 (23) , 679.

Garcia-Manero, Guillermo, Sekeres, Mikkael A., Egyed, Miklos, Alimena, Giuliana, Graux, Carlos, Cavenagh, Jamie D., Salman, Huda, Illes, Arpad, Fenaux, Pierre, DeAngelo, Daniel J., Stauder, Reinhard, Yee, Karen, Zhu, Nancy Y., Lee, Je-Hwan, Valcarcel, David, MacWhannell, Alan, Borbenyi, Zita, Wegener, Antje, Gazi, Lucien, Acharyya, Suddhasatta, Binlich, Florence and Ottmann, Oliver 2015. Panobinostat plus azacitidine in adult patients with MDS, CMML, or AML: results of a Phase 2b study. Blood 126 (23) , 2861.

Bartels, M., Nagel, I., Ussat, S., Ottmann, Oliver, Pfeifer, H., Trautmann, H., Boettcher, S., Goekbuget, N., Kneba, M., Oberg, H. -H., Siebert, R. and Brueggemann, M. 2015. Deletions of CDKN2A/B and PAX5 are frequently restricted to the CD19+compartment and associated with concurrent deletions of ABL in adult BCR-ABL plus BCP-ALL. Oncology Research and Treatment 38 , pp. 90-91.

Dengler, J., Le Coutre, P., Mueller, M. C., Stegelmann, F., Ulshoeer, T., Sauer, A., Reichert, D., Schwinger, U., Waller, C. F., Schardt, C., Losem, C., Schneider-Kappus, W., Stern, S., Vehling-Kaiser, U., Meincke, M., Frank, O. and Ottmann, Oliver 2015. Efficacy and safety of nilotinib in routine healthcare: Treatment of CML patients (pts) failing prior therapy - Results of the non-interventional TARGET study. Oncology Research and Treatment 38 (Supp 5) , pp. 132-133.

Pfeifer, H., Cayuela, J. -M., Spiekermann, K., Beck, J., Jung, W., Viardot, A., Schaefer-Eckhart, K., Reichle, A., Maury, S., Schmitz, N., Heidenreich, D., Panse, J., Junghanss, C., Raffoux, E., Suarez, F., Guillerm, G., Alexis, M., Lissandre, S., Huguet, F., Isnard, F., Lepetre, S., Escofffre-Barbe, M., Ribera, J. -M., Goekbuget, N., Dombret, H., Hoelzer, D., Rousselot, P. and Ottmann, Oliver 2015. European working group for adult ALL phase II trial of nilotinib in combination with chemotherapy for first-line treatment in elderly patients with de novo Philadelphiachromosome positive acute lymphoblastic leukemia (EWALL-PH-02). Oncology Research and Treatment 38 (Supp 5) , p. 88. 10.1159/000439070

Baerlocher, Gabriela M., Oppliger Leibundgut, Elisabeth, Ottmann, Oliver, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Röth, Alexander, Daskalakis, Michael, Burington, Bart, Stuart, Monic and Snyder, David S. 2015. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. New England Journal of Medicine 373 (10) , pp. 920-928. 10.1056/NEJMoa1503479

Seggewiss-Bernhardt, Ruth, Bargou, Ralf C., Goh, Yeow Tee, Stewart, A. Keith, Spencer, Andrew, Alegre, Adrian, Blade, Joan, Ottmann, Oliver, Fernandez-Ibarra, Cristina, Lu, Hong, Pain, Scott, Akimov, Mikhail and Iyer, Swaminathan Padmanabhan 2015. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121 (13) , pp. 2185-2192.

Fiedler, W., Heuser, M., Ottmann, Oliver, Kebenko, M., Thol, F., Trummer, A., Brandts, C., Bokemeyer, C., Theile, S. and Kranich, A. 2015. Preliminary phase II results of Ara-C and idarubicin in combination with selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Haematologica 100 , p. 221.

DeAngelo, Daniel J., Sekeres, Mikkael A., Ottmann, Oliver, Sanz, Miguel A., Naoe, Tomoki, Taube, Tillmann, Belsack, Valerie, Ge, Miaomiao and Doehner, Hartmut 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15 , S194-S194. 10.1016/j.clml.2015.04.046

Bartels, M., Nagel, I., Ussat, S., Ottmann, Oliver, Pfeifer, H., Trautmann, H., Boettcher, S., Goekbuget, N., Kneba, M., Oberg, H. H., Siebert, R. and Brueggemann, M. 2015. Clonal Architectures Of Bcr-Abl Plus Bcp-All: Implications For Anti B-Cell Directed Therapy. Haematologica 100 , p. 27.

Pfeifer, H., Rousselot, P., Cayuela, J. M., Karsten, S., Beck, J., Jung, W. E., Viardot, A., Schaefer-Eckart, K., Reichle, A., Maury, S., Schmitz, N., Heidenreich, D., Panse, J., Junghanss, C., Raffoux, E., Suarez, F., Guillerm, G., Alexis, M., Lissandre, S., Huguet, F., Isnard, F., Lepretre, S., Escoffre-Barbe, M., Ribera, J. M., Goekbuget, N., Hoelzer, D., Dombret, H. and Ottmann, Oliver 2015. Nilotinib In Combination With Chemotherapy For First-Line Treatment In Elderly Patients With Philadelphia-Positive All: Results Of The European Working Group For Adult All(Ewall-Ph-02). Haematologica 100 , pp. 6-7.

Ottmann, Oliver, Charbonnier, A., Stegelmann, F., Breccia, M., Steegmann, J. L., Olavarria, E., Jevtic, S., Cota, M., Scheuer, N. and Lipton, J. H. 2015. Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study. Haematologica 100 , pp. 62-63.

Mian, A. A., Rafiei, A., Haberbosch, I., Zeifman, A., Titov, I., Stroylov, V., Metodieva, A., Stroganov, O., Novikov, F., Brill, B., Chilov, G., Hoelzer, D., Ottmann, Oliver and Ruthardt, Martin 2015. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph plus ) leukemias harboring the T315I mutation. Leukemia 29 (5) , pp. 1104-1114.

Mian, A. A., Rafiei, A., Haberbosch, I., Zeifman, A., Titov, I., Stroylov, V., Metodieva, A., Stroganov, O., Novikov, F., Brill, B., Chilov, G., Hoelzer, D., Ottmann, Oliver and Ruthardt, Martin 2015. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29 (5) , pp. 1104-1114. 10.1038/leu.2014.326

Radich, Jerry, Rafiei, Anahita, Mian, Afsar Ali, Doering, Claudia, Metodieva, Anna, Oancea, Claudia, Thalheimer, Frederic B., Hansmann, Martin Leo, Ottmann, Oliver and Ruthardt, Martin 2015. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive Acute Lymphatic Leukemia. PLOS Genetics 11 (4) , e1005144. 10.1371/journal.pgen.1005144

Thol, Felicitas, Scherr, Michaela, Kirchner, Aylin, Shahswar, Rabia, Battmer, Karin, Kade, Sofia, Chaturvedi, Anuhar, Koenecke, Christian, Stadler, Michael, Platzbecker, Uwe, Thiede, Christian, Schroeder, Thomas, Kobbe, Guido, Bug, Gesine, Ottmann, Oliver, Hofmann, Wolf-Karsten, Kroeger, Nicolaus, Fiedler, Walter, Schlenk, Richard, Doehner, Konstanze, Doehner, Hartmut, Krauter, Juergen, Eder, Matthias, Ganser, Arnold and Heuser, Michael 2015. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica 100 (4) , E122-E124. 10.3324/haematol.2014.120345

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver, Radsak, M., Wolff, T., Haase, D., Hankin, M., Wilson, D., Zhang, X., Laadem, A., Sherman, M. and Attie, K. 2015. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Leukemia Research 39 (Supp 1) , S25-S25.

Brissot, Eolia, Labopin, Myriam, Beckers, Marielle M., Socie, Gerard, Rambaldi, Alessandro, Volin, Liisa, Finke, Juergen, Lenhoff, Stig, Kroeger, Nicolaus, Ossenkoppele, Gert J., Craddock, Charles F., Yakoub-Agha, Ibrahim, Gurman, Gunhan, Russell, Nigel H., Aljurf, Mahmoud, Potter, Michael N., Nagler, Armon, Ottmann, Oliver, Cornelissen, Jan J., Esteve, Jordi and Mohty, Mohamad 2015. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100 (3) , pp. 392-399. 10.3324/haematol.2014.116954

Bug, G., Burchert, A., Wagner, E. M., Kroeger, N., Jedlickova, Z., Gueller, S., Wolf, A., Huenecke, S., Bader, P., Serve, H. and Ottmann, Oliver 2015. Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial. Bone Marrow Transplantation 50 , S59-S59. 10.1038/bmt.2015.27

Mian, Afsar A., Haberboseh, Isabella, Kidan, Noa, Khamaisic, Hazem, Regev, Ofer, Nickola, Meshel, Gal, Maayan, Bloch, Etai, Ratiei, Anahita, Silani, Daryuseh, Ottmann, Oliver, Biondi, Ricardo, Ruthardt, Martin and Mahaina, Jamal 2015. Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. International Journal of Molecular Medicine 36 , S26-S26.

Tesanovic, Tamara, Badura, Susanne, Oellerich, Thomas, Doering, Claudia, Ruthardt, Martin and Ottmann, Oliver 2014. Mechanisms of antileukemic activity of the multikinase inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) harboring the E2A-PBX1 fusion gene. Blood 124 (21) , 3595.

Baerlocher, Gabriela M., Haubitz, Monika, Ottmann, Oliver, Odenike, Olatoyosi, Roeth, Alexander, McDevitt, Michael A., Shih, Ted, Burington, Bart, Morfeld, Dianne, Batra, Neeru, Snyder, David and Leibundgut, Elisabeth Oppliger 2014. Monitoring of Calr Allele burden in patients with Essential Thrombocythemia treated with Imetelstat, a telomerase inhibitor, reveals rapid and substantial molecular responses. Blood 124 (21) , 408.

Zweidler-McKay, Patrick A., DeAngelo, Daniel J., Douer, Dan, Dombret, Herve, Ottmann, Oliver, Vey, Norbert, Thomas, Deborah A., Zhu, Lili, Huang, Fei, Bajaj, Gaurav and Fischer, Bruce S. 2014. The safety and activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with anti-notch activity, in patients with relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): initial results of a phase 1 trial. Blood 124 (21) , 968.

Wojcik, Bartosch, Lang, Fabian, Badura, Susanne, Vogel, Anja, Tesanovic, Tamara, Oellerich, Thomas, Schroeder, Timm, Falkenburg, J. H. Frederik, Brueggemann, Monika, Ottmann, Oliver and Rieger, Michael A. 2014. Functional analysis of the subclonal architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a single cell level. Blood 124 (21) , 3778.

Mian, Afsar, Haberbosch, Isabella, Ottmann, Oliver and Ruthardt, Martin 2014. Transphosphorylation of endogenous BCR mediates the effect of T315I on the transformation potential of BCR/ABL. Blood 124 (21) , 4523.

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver, Radsak, M. P., Wolff, T., Haase, D., Hankin, M., Wilson, D. M., Laadem, A., Sherman, M. L. and Attie, K. M. 2014. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Blood 124 (21) , 411.

Oancea, Claudia, Heinssmann, Maria, Guillen, Nathalie, Ottmann, Oliver and Ruthardt, Martin 2014. The GSK3 beta-phosphorylation sites in the dek-portion are indispensable for the leukemogenic potential of the dek/can fusion protein in t(6;9)-positive acute myeloid leukemia [Abstract]. Blood 124 (21)

Mian, Afsar, Rafiei, Anahita, Oancea, Claudia, Ottmann, Oliver and Ruthardt, Martin 2014. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome positive Acute Lymphatic Leukemia. Blood 124 (21) , 2402.

Scherr, M., Elder, A., Battmer, K., Barzan, D., Bomken, S., Ricke-Hoch, M., Schroeder, A., Venturini, L., Blair, H. J., Vormoor, J., Ottmann, Oliver, Ganser, A., Pich, A., Hilfiker-Kleiner, D., Heidenreich, O. and Eder, M. 2014. Differential expression of miR-17 similar to 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 28 (3) , pp. 554-565. 10.1038/leu.2013.361
file

Platzbecker, U., Al-Ali, H. K., Gattermann, N., Haase, D., Janzen, V., Krauter, J., Goetze, K., Schlenk, R., Nolte, F., Letsch, A., Ottmann, Oliver, Kuendgen, A., Luebbert, M., Germing, U., Wermke, M., Reinhard, H., Weiss, C., Lieder, K., Ehninger, G., Leismann, O. and Giagounidis, A. 2014. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients [Letter]. Leukemia 28 (3) , pp. 696-698. 10.1038/leu.2013.325

Stegelmann, F., Dengler, J., Le Coutre, P., Mueller, M. C., Sauer, A., Schwinger, U., Losem, C., Schneider-Kappus, W., Stern, S., Vehling-Kaiser, U., Meincke, M., Frank, O. and Ottmann, Oliver 2014. Follow-up of the non-interventional TARGET study – efficacy and safety of nilotinib in routine clinical management of CML patients (pts) failing prior therapy. Oncology Research and Treatment 37 (Supp 1) , p. 84.

Bug, Gesine, Koschmieder, Steffen, Krauter, Juergen, Heuser, Michael, Thol, Felicitas, Wiebe, Stefanie, Hofmann, Wolf-Karsten, Klein, Stefan A., Wegener, Gerd, Goehring, Gudrun, Heit, Wolfgang, Hoelzer, Dieter, Ganser, Arnold and Ottmann, Oliver 2014. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Annals of Hematology 93 (2) , pp. 193-202. 10.1007/s00277-013-1873-3

Jabbour, Elias, Ottmann, Oliver, Deininger, Michael and Hochhaus, Andreas 2014. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 99 (1) , pp. 7-18. 10.3324/haematol.2013.087171
file

Ottmann, Oliver, Pfeifer, Heike, Cayuela, Jean-Michel, Spiekermann, Karsten, Beck, Joachim, Jung, Wolfram E., Viardot, Andreas, Kerstin, Schaefer-Eckart, Reichle, Albrecht, Maury, Sebastien, Schmitz, Norbert, Heidenreich, Daniela, Panse, Jens, Junghanss, Christian, Raffoux, Emmanuel, Suarez, Felipe, Guillerm, Gaeelle, Alexis, Magda, Lissandre, Severine, Huguet, Francoise, Isnard, Francoise, Lepretre, Stephane, Escoffre-Barbe, Martine, Ribera, Josep-Maria, Goekbuget, Nicola, Dombret, Herve, Hoelzer, Dieter and Rousselot, Philippe 2014. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood 124 (21) , p. 798.

Doehner, Hartmut, Luebbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver, Mueller-Tidow, Carsten, Kraemer, Alwin, Raffoux, Emmanuel, Doehner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger and Maertens, Johan 2014. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 124 (9) , pp. 1426-1433. 10.1182/blood-2014-03-560557

This list was generated on Tue Nov 13 04:18:33 2018 GMT.